Yesterday, we reported positive clinical study results into a symptomatic treatment for Parkinson’s disease from Biotie Therapies, which targets a brain chemical called adenosine. And today, a quick addendum, as more positive trial results focused on adenosine were announced from another company – the British-based Vernalis.
According to Vernalis, the study confirmed the appropriate dose of their drug, called V8144, to be used in a forthcoming phase 2 trial, which is scheduled to begin in the first half of 2013.
Merck also has a Parkinson's drug targeting adenosine in the third phase of clinical testing.